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Background: Toll-like receptors (TLR) are a family of pattern recognition receptors that constitutes a major part of
the innate immune system. The TLR4/(Myeloid differentiation factor 88 (MyD88) signaling pathway has been shown
to have oncogenic effects.
Methods: To demonstrate the role of TLR4/MyD88 signaling in ovarian epithelial cancers (OECs), we examined the
expression of TLR4, MyD88 and nuclear factor- κB (NF-κB) in OECs. The expression of TLR4, MyD88, and NF-κB was
detected by immunohistochemistry, and the relationships between these and clinicopathologic features in 123
cases of OECs were also analyzed.
Results: The expression of TLR4, MyD88, and NF-κB in OECs was observed in 46.3% (57/123), 36.6% (45/123) and
65% (80/123) of OEC cases, respectively. The TLR4, MyD88, and NF-κB expressions were associated with the
histologic type of OECs, particularly with the clear cell type of OEC. There was no significant correlation between
TLR4 or NF-κB expression and histologic grade, tumor size, mitotic count, FIGO (International Federation of
Gynecology and Obstetrics) stage, disease recurrence. However, there was a significant correlation between MyD88
expression and FIGO stage, disease recurrence as well as histologic type. In univariate analysis, the expression of
TLR4 and MyD88, and the coexpression of TLR4/MyD88 and TLR4/MyD88/NF-κB had a significant impact on the
survival of patients with OECs. Only MyD88 expression had an independent prognostic significance in multivariate
analysis.
Conclusions: Our findings suggest that the TLR4/MyD88 signaling pathway is associated with the survival of
patients with OECs, and that MyD88 is an independent prognostic predictor in patients with OECs. The TLR4/
MyD88 signaling pathway may be a mechanism responsible for poor prognosis in patients with clear cell type of OEC.
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Ovarian epithelial cancer (OEC) is the second most
common and the most lethal of all gynecologic malig-
nancies. Early detection of OEC is difficult because there
is no specific screening tool and long-term survival has
not been significantly prolonged although many
advances have been made in the treatment of OEC.* Correspondence: kuchoi@pusan.ac.kr
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reproduction in any medium, provided the orMany investigators have tried to understand the biology
of OEC and identify the mechanisms of chemoresis-
tance, which is one of the major causes of treatment
failure for OEC.
The toll-like receptors (TLRs) are surface molecules
on eukaryotic cells that detect and respond to microbial
infection. TLRs are the best studied of a class of host
receptors known as pattern recognition receptors
(PRRs). TLRs are central to the regulation of host pro-
tective adaptive immune responses. In humans, 13 types
of TLRs have been identified, and are mainly expressed
by immune cells and epithelial cells. Recently, TLRs have
also been detected in many tumor cell lines or tumors,
especially epithelial-derived cancers [1]. Recent evidence. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient and tumor characteristics
Characteristics N (%)
Histologic type Serous 60 (48.8)
Mucinous 25 (20.3)
Endometrioid 11 (8.9)
Clear cell 25 (20.3)
Undifferentiated 2 (1.6)
Histologic grade Grade 1 35 (28.5)
Grade 2 62 (50.4)
Grade 3 26 (21.1)
Tumor size <10 cm 61 (49.6)
≥10 cm 62 (50.4)
Mitotic count <10/10HPFs 50 (40.6)
10 ≤ but < 20/10HPFs 44 (35.8)
≥20/10HPFs 29 (23.6)




Disease recurrence No 62 (50.4)
Yes 61 (49.6)
Survival Alive 92 (74.8)
DOD 31 (25.2)
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variety of tumors [2]. TLRs may promote the prolifera-
tion and inhibit the apoptosis, and lead to migration, in-
vasion and angiogenesis of tumors [3]. Most TLRs share
a common adaptor molecule, myeloid differentiation
primary-response protein (MyD88), to activate nuclear
factor- κB (NF-κB) and mitogen-activated protein
kinases (MAP kinases) and induce expression of various
inflammatory cytokine genes [4]. In a murine model of
liver carcinogenesis induced by injection of the mutagen
diethylnitroseamine, MyD88-dependent signaling has
been shown to be critical for tumorigenesis [5]. MyD88
has also recently been shown to be crucial for tumor
promotion in models of spontaneous and carcinogen-
induced (azoxymethane) intestinal tumorigenesis [6,7].
TLRs are supposed to be expressed in the female geni-
tal tract and may play an essential role in the defense
against microbes [8]. Current studies suggest a link be-
tween TLR signaling and tumorigenesis and tumor pro-
gression in the human female reproductive tract. Recent
work has also suggested the role of TLR4 in the propa-
gation of OECs [9]. They showed that TLR4 and MyD88
were expressed in tumor cells of OEC both at the
mRNA and protein level, and that the TLR4 induces
NF-κB activation in MyD88-positive OEC cells. They
also suggested that the MyD88 status of OCE cells deter-
mines the apoptotic response to paclitaxel. However, the
data available so far are still limited and most evidences
are the results of in vitro research on cell lines. Also, the
biological significances of TLRs expressed on tumor cells
of the genital tract have not been fully elucidated yet.
We propose that the TLR4/MyD88 signaling pathway
may be a risk factor for developing cancer and may rep-
resent a novel target for the development of biomodula-
tors for treatment of OECs. We tried to determine the
expression and prognostic associations of TLR4/MyD88
pathway proteins in various histologic types of OECs.
In this study, we performed an immunohistochemical
analysis of TLR4, MyD88 and NF-κB expression and
analyzed the associations between their immunoreactivity
and clinicopathologic features in OECs.
Methods
Patients and tissue
A total of 123 patients with OECs who underwent
surgery and were diagnosed between 1998 and 2008
were selected from the archives of the Pusan National
University Hospital for this study. All the cases were of
primary OECs. Hematoxylin and eosin (H&E) stained
sections were reviewed and subclassified according to
the WHO (World Health Organization) guidelines. The
tumor stage was determined by FIGO (International
Federation of Gynecology and Obstetrics) classification,
and cases was classified by the Silverberg tumor gradesystem. The mean age of patients at the time of surgery
was 51 years (range, 15 to 82 years). Clinicopathologic
characteristics are shown in Table 1. All patients, except
those with grade 1, stage IA, were given adjuvant
chemotherapy consisting of platinum/Taxol-containing
agents. They were followed up for 3 to 140 months
(mean follow-up period, 43 months). During this follow-
up period, 61 patients (49.6%) developed recurrent
disease and 31 patients (25.2%) died from the disease.
Normal ovaries obtained from ten patients who under-
went surgery for benign gynecologic disease were
included as a control. Written informed consent was
obtained from the patient for publication of this report
and any accompanying images. Ethical approval for
the project was obtained from the Pusan National
University Hospital Research Ethics Committee
(PNUH IRB #2010085).
Immunohistochemistry
The tissue specimens were fixed in 10% formalin and
embedded in paraffin. Slides, 4 μm in thickness, were
deparaffinized in xylene and rehydrated through a series
of graded ethanol. Endogenous peroxidase activity was
blocked by incubation with 3% hydrogen peroxide in
methanol for 10 minutes. Antigen retrieval was per-
formed by microwaving the slides in citrate buffer
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overnight with anti-TLR4 antibody (mouse monoclo-
nal, HTA125, 1:100; eBioscience, San Diego, CA,
USA), anti-MyD88 antibody (rabbit polyclonal, HFL-296,
1:100; Santa Cruz Biotech, Santa Cruz, CA, USA), or anti-
NF-κB p65 antibody (mouse monoclonal, F-6, 1:100; Santa
Cruz Biotech, Santa Cruz, CA, USA). Immunoreactivity
was visualized using 3,3'-diaminobenzidine (DAB, Dako-
Cytomation, Glostrup, Denmark). Slides were counter-
stained with Meyer's hematoxylin. Human tonsil
tissue was used as a positive control and phosphate-
buffered saline without the primary antibody served
as a negative control.
Each slide was evaluated independently by two
pathologists who were blinded to clinical and out-
come data. The assessment of TLR4, MyD88, and
NF-κB expression was based on previously described
guidelines [10,11]. Their expressions were assessed
semi-quantitatively based on the percentage of stained
tumor cells and the staining intensity. The percentage
of positive tumor cells was rated as follows: 1 point,
≤ 10% positive tumor cells; 2 points, 11%-50% posi-
tive tumor cells; 3 points, 51%-80% positive tumor
cells; and 4 points, ≥81% positive tumor cells. The
staining intensity was rated as follows: 1 point, weak
intensity; 2 points, moderate intensity; and 3 points,
strong intensity. Points for expression and percentage
of positive cells were added, and specimens were
attributed to four groups according to their overall score:
negative, ≤10% of cells stained positive, regardless of
intensity; weak expression, 3 points; moderate expression,
4 to 5 points; and strong expression, 6 to 7 points. Weak
expression was rated as negative, and moderate and strong
expressions were rated as positive for analysis.
Statistical analysis
For statistical analysis, SPSS 15.0 (SPSS Inc. Chicago, IL,
USA) was used. The χ2 test was used to evaluate the cor-
relation between the expression of TLR4, MyD88, and
NFκB, and the clinicopathologic parameters. The linear
correlations for expression were assessed using the Pear-
son correlation coefficient. Survival analysis was per-
formed using the Kaplan-Meier method; univariate
and multivariate Cox regression analyses were used
to identify variables associated with overall survival
(OS). P values of < 0.05 were considered statistically
significant.
Results
TLR4 protein was detected by immunohistochemistry
and was localized in the cytoplasm and membrane of
the tumor cells (Figure 1). The positive expression of
TLR4 was observed in 57 cases (46.3%) of OECs. When
analyzing the relationship between TLR4 expression andclinicopathological features, we found that the expres-
sion of TLR4 was not correlated with histologic grade,
tumor size, mitotic count, tumor stage and tumor recur-
rence, but it was significantly correlated with histologic
type. MyD88 was expressed in the cytoplasm of the
tumor cells and the positive expression of MyD88 was
observed in 45 cases (36.6%) of OECs, and it had a sig-
nificant correlation with tumor stage, tumor recurrence
and histologic type. NF-κB expression was recognized
through cytoplasmic and/or nuclear staining of the
tumor cells and was observed in 80 cases (60%) of OECs.
No correlation between NF-κB expression and clinico-
pathological features was observed, except for histologic
type. TLR4, MyD88, and NF-κB expressions were signifi-
cantly higher in clear cell type of OECs than in the other
histologic types of OECs (Table 2).
TLR4 and MyD88 were co-expressed in 31 cases
(25.2%) of OECs. TLR4, MyD88 and NF-κB were co-
expressed in 26 cases (21.1%) of the OECs. The co-
expression of TLR4/MyD88 or TLR4/MyD88/NF-κB in
relation to clinicopathologic features is shown in Table 3.
The co-expression of TLR4/MyD88 or TLR4/MyD88/
NF-κB was significantly associated with tumor stage and
histologic type. To study the association between TLR4,
MyD88 and NF-κB, we performed the correlation ana-
lysis. The results showed that there was a significant
correlation between the expression of TLR4 and MyD88
(r = 0.343, P = 0.000) (Table 4).
We assessed the impact of expression of TLR4,
MyD88 and NF-κB on patient survival. The mean sur-
vival of patients with expression of TLR4 in tumor tis-
sues was 88.3 months, and it was 113.1 months in those
with negative expression of TLR4, Kaplan-Meier analysis
showed that there was a significant difference in the
mean survival of patients with expression of TLR4 in
tumor tissues and in those with negative expression of
TLR4 (P = 0.030) (Figure 2A). Patients with positive
MyD88 expression had a worse OS than those with
negative MyD88 expression (65.2 months versus
121.1 months) (P = 0.000) (Figure 2B). Similar results
were also found between co-expression of these proteins
and OS (Table 5 and Figure 2C and 2D). In multivariate
analysis, MyD88 was identified as an independent
prognostic factor (Table 6).
Discussion
TLRs are a family of PRRs that are best-known for their
role in host defense against infection. There is increasing
evidence that TLR signaling pathway is involved in
tumorigenesis and chemoresistance. TLR-variants are
known to be associated with cancer risk. Sequence
variants of TLR4 are associated with prostate cancer risk
and sequence variants of TLR4 and TLR10 are asso-
ciated with nasopharyngeal cancer risk [12,13]. The risk
Figure 1 OECs showed the expressions of TLR4, MyD88, and NF-κB. (A) Serous type, TLR4, (B) serous type, MyD88, (C) serous type, NF-κB,
(D) mucinous carcinoma, TLR4, (E) mucinous carcinoma, MyD88, (F) mucinous carcinoma, NF-κB, (G) clear cell type, TLR4, (H) clear cell type,
MyD88, (I) clear cell type, NF-κB, (J) undifferentiated type, TLR4, (K) undifferentiated type, MyD88, (L) undifferentiated type, NF-κB. OECs, Ovarian
epithelial cancers.
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connected to polymorphism of TLRs [14].
TLRs are expressed on cells of the immune system but
TLRs are also expressed on tumor cells. These expres-
sions were observed in human tumor cells lines, such as
colon, breast, and melanoma, as well as murine tumor
cell lines, including colon, breast, prostate, lung and
melanoma.MyD88 plays a critical role in TLR signaling. TLRs
generally signal through a MyD88-dependent manner,
leading to a proinflammatory response. Signaling via
MyD88 involves the early phase of NF-κB activation,
which leads to the production of proinflammatory cyto-
kines. Some experimental studies have identified the
contribution of TLR4/MyD88 signaling to intestinal
carcinogenesis. Wang et al. [15] demonstrated that
Table 2 Relationship between TLR4, MyD88 and NF-κB
TLR4 MyD88 NF-κB
Positive Negative P Positive Negative P Positive Negative P
Histologic type Serous 23 37 0.001 20 40 0.003 40 20 0.037
Mucinous 6 19 5 20 15 10
Endometrioid 7 4 2 9 4 7
Clear cell 19 6 16 9 20 5
Undifferentiated 2 0 2 0 1 1
Histologic grade Grade 1 15 20 0.469 8 27 0.083 25 10 0.640
Grade 2 32 30 24 38 39 23
Grade 3 10 16 13 13 16 10
Tumor size <10 cm 26 35 0.471 24 37 0.577 39 22 0.851
≥10 cm 31 31 21 41 41 21
Mitotic count <10/10HPFs 25 25 0.569 16 34 0.660 35 15 0.541
10≤ but <20/10HPFs 21 23 18 26 26 18
≥20/10HPFs 11 18 11 18 19 10
FIGO stage I/II 26 36 0.368 16 46 0.015 38 24 0.451
III/IV 31 30 29 32 42 19
Disease recurrence No 27 35 0.589 16 46 0.015 40 22 0.526
Yes 30 31 29 32 40 21
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immunohistochemistry on paraffin blocks of colorectal
cancers and showed that TLR4/MyD88 expression was
associated with liver metastasis and was an independent
predictor of poor prognosis in patients with colorectalTable 3 Relationships between co-expression of TLR4/MyD88
TLR4
Positive N
Histologic type Serous 12 4
Mucinous 2 2
Endometrioid 2 9
Clear cell 13 1
Undifferentiated 2 0
Histologic grade Grade 1 4 3
Grade 2 20 4
Grade 3 7 1
Tumor size <10 cm 17 4
≥10 cm 14 4
Mitotic count <10/10HPFs 10 4
10 ≤ but < 20/10HPFs 14 3
≥20/10HPFs 7 2
FIGO stage I/II 10 5
III/IV 21 4
Disease recurrence No 13 4
Yes 18 4cancer. Their findings suggest that TLR4/MyD88 signaling
promotes colorectal cancer progression by contributing to
liver metastasis. In pancreatic ductal adenocarcinoma
(PDAC), TLR4 was expressed in the tumor cells and was
related to the survival of patients with PDAC [11].signaling pathway proteins and clinicopathologic factors
/MyD88 TLR4/MyD88/NF-κB
egative P Positive Negative P





1 0.074 3 32 0.058
2 18 44
9 5 21
4 0.539 13 48 0.569
8 13 49
0 0.415 9 41 0.707
0 11 33
2 6 23
2 0.023 8 54 0.028
0 18 43
9 0.305 11 51 0.384
3 15 46
Table 4 Correlation among TLR4, MyD88 and NF-κB
TLR4 MyD88 NF-κB
TLR4 Pearson Correlation - 0.343 0.066
0.000 0.469P value
MyD88 Pearson Correlation - - 0.097
0.287P value
Figure 2 The Kaplan-Meier curves revealed the correlation between t
NF-κB, and the overall survival (A-D).
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demonstrated by stimulation of cell lines with specific
ligands and subsequent activation and translocation of
NF-κB and release of the proinflammatory cytokines
interleukin-6 and CCL-2 [16]. Kelly et al. demonstrated
for the first time the expression of TLR4 in OEC cells,
the induction of tumor growth by TLR4 ligation in
MyD88-positive OEC cells, and chemoresistance to
paclitaxel mediated by the expression of MyD88. Theyhe expression of TLR4, MyD88, TLR4/MyD88 and TLR4/MyD88/
Table 5 Univariate analysis of TLR4/MyD88 signaling






TLR4 Positive 88.3 72.5 104.1 0.030
Negative 113.1 97.8 128.4
MyD88 Positive 65.2 51.2 79.2 0.000
Negative 121.1 109.4 132.8
TLR4/MyD88 Positive 59.1 43.7 74.5 0.000
Negative 113.9 101.9 125.9
TLR4/MyD88/
NF-κB
Positive 56.5 39.5 73.5 0.000
Negative 112.0 100.0 124.0
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MyD88 had a significantly worse progression-free inter-
val compared with patient whose tumors did not express
MyD88. In this study, we included a large number of
cases of OECs and various histologic subtypes of OECs
and tried to demonstrate the expression of TLR4/
MyD88 signaling pathway proteins in tumor cells using
an immunohistochemical method. We found that TLR4,
MyD88 and N-FκB were frequently expressed in tumor
cells of OECs and that expression of TLR4, MyD88,
TLR4/MyD88 and TLR4/MyD88/NF-κB was associated
with overall survival in patients with OECs. Particularly,
MyD88 had an independent prognostic significance, and
there was positive correlation between the expression of
MyD88 and TLR4. Our findings suggest that TLR4/
MyD88 signaling promotes OEC progression and that
MyD88 plays a central role in OEC progression.
Our study also showed that the percentage of TLR4,
MyD88 and NF-κB expression was significantly higher
in the clear cell type of OEC than in the other types of
OECs. Clear cell ovarian carcinoma has been known to
show a poor prognosis, which is associated with the
resistance to conventional platinum-based chemotherapy
[17,18]. Several mechanisms have been proposed to be
involved in drug resistance, including the lower pro-
liferation of tumors, decreased drug accumulation,
and increased DNA repair activity [18-20]. We
mentioned the significance of TLR4/MyD88 signalingTable 6 Multivariate analysis of TLR4/MyD88 signaling







TLR4 0.168 0.409 0.115 1.457
MyD88 0.004 0.128 0.032 0.513
TLR4/MyD88 0.438 2.580 0.235 28.300
TLR4/MyD88/NF-κB 0.551 0.553 0.079 3.883pathway in progression of OECs and suggest that the
TLR4/MyD88 signaling pathway may be one of the
mechanisms involved in drug resistance, and is especially
associated with the poor prognosis of clear cell type
of OECs.
Recent works have suggested a role for NF-κB in
tumors of epithelial origin, including breast, colon, lung,
and ovarian carcinomas [21,22]. Annunziata et al.
reported a significant association of NF-κB p50 with
poor overall survival in patients with OECs and
suggested that the deregulation of NF-κB activity may
influence outcome in patients who receive conventional
chemotherapy for OECs. Our data showed that NF-κB
p65 was frequently expressed in OECs, however, its
expression was not associated with clinicopathologic
factors of OECs, including overall survival. When NF-κB
p65 was expressed in association with TLR4 and
MyD88, it led to poor survival.
Conclusions
Our study for the first time revealed that TLR4, MyD88,
and NF-κB were expressed in the tumor cells of a large
number of OECs using immunohistochemistry. Our data
indicated that TLR4/MyD88 signaling pathway may con-
tribute to progression of OECs and MyD88 expression is
significantly associated with poor survival in patients
with OECs. TLR4, MyD88 and NF-κB expression was
more frequently observed in the clear cell type of OEC.
These findings suggested the association of drug resistance
with poor prognosis of clear cell type of OEC and the
novel therapeutic possibility of targeting tumor cells.
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